Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr;29(2):345-348.
doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L Chan  1 , Stephen L Chan  1   2
Affiliations
Editorial

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L Chan et al. Clin Mol Hepatol. 2023 Apr.
No abstract available

Keywords: Chemoembolization; Hepatocellular carcinoma; Immune checkpoint inhibitors; Lenvatinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

S.L. Chan is the advisory for Astra-Zeneca, MSD, Eisai, BMS and Roche. S.L. Chan received research fund from MSD, Bayer, Eisai, Ipsen and SIRTEX. S.L. Chan received Honoraria from Bayer, Astra-Zeneca, Eisai, Roche and MSD. S.L. Chan is the speaker for MSD, BMC, Astra-Zeneca, Eisai, Roche, Ipsen, SIRTEX and Hutchmed.

Comment on

References

    1. Hui RW, Mak LY, Cheung TT, Lee VH, Seto WK, Yuen MF. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2023;29:217–229. - PMC - PubMed
    1. Chan SL, Wong N, Lam WKJ, Kuang M. Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. J Gastroenterol Hepatol. 2022;37:1197–1206. - PubMed
    1. Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol. 2023;78:207–216. - PMC - PubMed
    1. Sohn W, Kang D, Kang M, Guallar E, Cho J, Paik YH. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. Clin Mol Hepatol. 2022;28:851–863. - PMC - PubMed
    1. Kim BH, Cho Y, Park JW. Surveillance for hepatocellular carcinoma: It is time to move forward. Clin Mol Hepatol. 2022;28:810–813. - PMC - PubMed

Substances